GSK launches phase III trial for inhaled triple combination therapy

GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) said today that they launched a phase III trial evaluating the triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) in patients with asthma.

The companies’ triple combination therapy is made up of 3 drugs – an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting beta-adrenergic agonist. The treatment is delivered once a day using GSK’s Ellipta dry powder inhaler.

Get the full story at our sister site, Drug Delivery Business News.

The post GSK launches phase III trial for inhaled triple combination therapy appeared first on MassDevice.

from MassDevice http://ift.tt/2i76F91